Login

Ownership

13F as of Q3 2026 · 26.8M shares outstanding

Who owns Syros Pharmaceuticals, Inc.?

By type of holder
Institutions 0.0% Everyone else 100.0%

No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".

Concentration Top 3 holders own 7.9%
Samsara BioCapital, L.P. 2.6% · Samsara BioCapital GP, LLC 2.6%
Institutional ownership
0.0%
0.0 pts vs last qtr
Institutional holders
0
0 vs last qtr
Net shares bought
0
by institutions in Q3 2026
New / sold out
0 / 0
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q3 2026

None.

Biggest sellers in Q3 2026

None.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Syros Pharmaceuticals, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2016–FY2023
+123.1%
+12.15% a year
Each share's claim on the business
−55.2%
shrank without buying or selling a share
Spent on buybacks vs paid in stock
— vs $68.2M
over 8 fiscal years
Diluted shares, split-adjusted
4.5M22.5M40.6M2016: 12.7M shares'162017: 25.4M shares'172018: 32.7M shares'182019: 40.2M shares'192020: 4.6M shares'202021: 6.3M shares'212022: 12.6M shares'222023: 28.3M shares'23
Buybacks Stock-based comp
$0$5.7M$11.4M2016 buybacks: $02016 stock comp: $4.2M'162017 buybacks: $02017 stock comp: $4.4M'172018 buybacks: $02018 stock comp: $6.6M'182019 buybacks: $02019 stock comp: $9.8M'192020 buybacks: $02020 stock comp: $10.9M'202021 buybacks: $02021 stock comp: $10.4M'212022 buybacks: $02022 stock comp: $11.4M'222023 buybacks: $02023 stock comp: $10.4M'23

How patient are the owners?

No 13F manager reports holding Syros Pharmaceuticals, Inc..

Super Investors

Investment managers reporting Syros Pharmaceuticals, Inc. on Form 13F
No 13F manager reports holding Syros Pharmaceuticals, Inc. yet.

Institutional Funds

Mutual funds and ETFs reporting Syros Pharmaceuticals, Inc. on Form N-PORT; together they hold 0.0% of the company
DE
Master Investment Portfolio
Position value
$0.09
% of company
0.00%
% of the fund
0.00%
As of
June 30, 2026
GA
Guggenheim Active Allocation Fund
Guggenheim Active Allocation Fund
Position value
$0.01
% of company
0.00%
% of the fund
0.00%
As of
August 31, 2026

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
SB
Samsara BioCapital, L.P.
5%+ holder13D · 2.6%
Shares
707.1K
% of company
2.64%
Change vs last qtr
—
Held since
—
SB
Samsara BioCapital GP, LLC
5%+ holder13D · 2.6%
Shares
707.1K
% of company
2.64%
Change vs last qtr
—
Held since
—

1 more holders behind a free account

See every insider and 5%+ holder of Syros Pharmaceuticals, Inc..

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support